New blood test helps detect Alzheimer's plaque in patients 55 and older
The FDA cleared the Lumipulse in May 2025 as a tool to identify amyloid plaque, offering an alternative to brain scans and spinal fluid tests for older adults with memory issues.
By Samuel Hayes ·

Diagnosing Alzheimer's disease often requires invasive procedures such as brain scans or spinal fluid analysis. A new blood test now offers a less intrusive option for older adults showing signs of cognitive decline. The Food and Drug Administration cleared the Lumipulse in May 2025. It is the first blood test approved by the agency to aid in diagnosing Alzheimer's disease.
The test detects amyloid plaque in the brain, a key marker of the condition. It is intended for patients 55 years of age or older who are already experiencing memory problems. Researchers indicate that a positive result suggests a greater than 90% chance that the patient has amyloid plaque in their brain. The FDA notes that the test is not a standalone diagnostic tool. Doctors must interpret the results alongside a patient's medical history and other assessments, such as cognitive testing.
Dr. Rhea Rogers, a board-certified physician and host of the program Aging Untold, described the test as a useful step for early evaluation. She stated, "It's a game changer. It's indicated for people who are 55 years of age or greater with symptoms of cognitive decline." Rogers explained that identifying the disease earlier allows individuals and their families to plan for care options. She added, "I think it's very welcoming because we know that like many diseases, especially Alzheimer's, the earlier that you catch it, the more you can make an impact on quality of life."
Kathi Rigby, who was diagnosed with Alzheimer's in 2022, illustrated the impact of early detection. She recalled a bike ride with her husband where she suddenly struggled to speak. "I couldn't get words from my brain to my mouth," Rigby said. The diagnosis, which she described as "like a slap in the face," allowed her to join a clinical trial for a drug designed to remove brain plaque. Her husband, Brent, reported that 95% of the plaque was removed during the trial. While Rigby's specific outcome does not guarantee results for other patients, she said the treatment made a difference in her life. "I want to be Grandma, and I want them to know that I love them, and I know them," she said.
The Lumipulse serves as an initial screening tool rather than a final verdict. It reduces the need for more complex imaging for qualifying patients. The test is available now for those meeting the age and symptom criteria. Physicians use the blood results to guide further medical decisions and care planning.






